La Trobe

Characterisation of novel influenza‐derived HLA‐B*18:01‐restricted epitopes

journal contribution
posted on 2025-01-08, 05:48 authored by Samuel LeongSamuel Leong, Lawton MurdoloLawton Murdolo, Janesha Chandimali MaddumageJanesha Chandimali Maddumage, Marios Koutsakos, Katherine Kedzierska, Anthony W Purcell, Stephanie GrasStephanie Gras, Emma GrantEmma Grant

Objectives: Seasonal influenza viruses cause roughly 650 000 deaths annually despite available vaccines. CD8+ T cells typically recognise influenza-derived peptides from internal structural and non-structural influenza proteins and are an attractive avenue for future vaccine design as they could reduce the severity of disease following infection with diverse influenza strains. CD8+ T cells recognise peptides presented by the highly polymorphic Human Leukocyte Antigens class I molecules (HLA-I). Each HLA-I variant has distinct peptide binding preferences, representing a significant obstacle for designing vaccines that elicit CD8+ T cell responses across broad populations. Consequently, the rational design of a CD8+ T cell-mediated vaccine would require the identification of highly immunogenic peptides restricted to a range of different HLA molecules.

Methods: Here, we assessed the immunogenicity of six recently published novel influenza-derived peptides identified by mass-spectrometry and predicted to bind to the prevalent HLA-B*18:01 molecule.

Results: Using CD8+ T cell activation assays and protein biochemistry, we showed that 3/6 of the novel peptides were immunogenic in several HLA-B*18:01+ individuals and confirmed their HLA-B*18:01 restriction. We subsequently compared CD8+ T cell responses towards the previously identified highly immunogenic HLA-B*18:01-restricted NP219 peptide. Using X-ray crystallography, we solved the first crystal structures of HLA-B*18:01 presenting immunogenic influenza-derived peptides. Finally, we dissected the first TCR repertoires specific for HLA-B*18:01 restricted pathogen-derived peptides, identifying private and restricted repertoires against each of the four peptides.

Conclusion: Overall the characterisation of these novel immunogenic peptides provides additional HLA-B*18:01-restricted vaccine targets derived from the Matrix protein 1 and potentially the non-structural protein and the RNA polymerase catalytic subunit of influenza viruses.

Funding

The investigation of an unconventional Human Leukocyte Antigen molecule

Australian Research Council

Find out more...

Understanding immunity to influenza B viruses for a rationally designed universal vaccine

National Health and Medical Research Council

Find out more...

Harnessing universal immunity to influenza

National Health and Medical Research Council

Find out more...

An integrated approach to antigen discovery in autoimmunity and cancer

National Health and Medical Research Council

Find out more...

T cell-mediated responses to influenza and Human Immunodeficiency virus (HIV) infection

National Health and Medical Research Council

Find out more...

Australian Institute of Nuclear Science and Engineering

La Trobe University

History

Publication Date

2024-01-01

Journal

Clinical and Translational Immunology

Volume

13

Issue

5

Article Number

e1509

Pagination

15p.

Publisher

Wiley

ISSN

2050-0068

Rights Statement

© 2024 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Usage metrics

    Journal Articles

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC